Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID).

After rituximab therapy, the proportion of patients using other therapies remained lower than use prior to rituximab, although the use of immunosuppressives showed a trend towards greater use compared with during rituximab (Table 3 ).

also in 53,322 other papers